Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects with allergic con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergy

Drugs mentioned

• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergy | Phase 1 | Status: COMPLETED